Telomere & telomerase biology
Epitalon is best known for research on telomerase and telomere length.
Explore the research →PINEAL, CIRCADIAN & AGEING RESEARCH
Epitalon
Epitalon is best known in longevity research, where interest centres on ageing, sleep and cellular health. Human evidence remains limited.
Telomere biologyCircadian rhythmCell ageing
Laboratory-led evidence with limited clinical translationRecent cell-line work strengthens the telomere mechanism story, while claims of longer life or broad rejuvenation remain unsupported by robust modern human trials.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why is Epitalon discussed in longevity research?
Epitalon has become closely associated with longevity because research around it touches on the body clock, melatonin, telomeres and the way cells respond to ageing. Together, those themes explain why it attracts people interested in sleep, cellular ageing and maintaining healthy function over time.
Circadian & pineal signalling
The peptide is discussed around pineal regulation and melatonin rhythms.
Explore the research →Cellular stress & ageing
Antioxidant and cell-maintenance mechanisms underpin broader healthy-ageing interest.
Explore the research →Retinal research
A small clinical literature has explored retinal degeneration.
Explore the research →THE SCIENCE BIT
Exploring signals at the ends of chromosomes.
Epitalon is a four-amino-acid peptide explored in cellular-ageing research. Cell experiments report telomerase-related activity and changes in telomere length—the protective ends of chromosomes.
Those observations are interesting because telomeres are part of cell biology, but longer telomeres in a laboratory dish do not establish longer life in people. Pineal and circadian research adds another, still developing, angle.
See the studies & trials →- Telomeres
- Chromosome-end biology
- Telomerase
- Activity examined in cells
- Circadian signals
- Pineal-related research
How this connects to the research
Experimental mechanisms; a human longevity effect has not been established.
FROM MOLECULE TO TISSUE
Where Epitalon connects with the body
These are the tissues and biological systems behind the interest in Epitalon.
- Cell nucleus
- Telomere experiments.
- Pineal system
- Body-clock hypotheses.
- Retina
- Small research programmes.
The research behind the interest
Telomere & telomerase biology
Epitalon is best known for research on telomerase and telomere length.
A 2025 cell-line study reported telomere extension through telomerase upregulation or ALT-related activity, including effects in cancer cell lines that require careful interpretation.
Laboratory evidenceExplore the studies →Circadian & pineal signalling
The peptide is discussed around pineal regulation and melatonin rhythms.
Most direct circadian evidence is preclinical or based on older regional studies rather than modern sleep trials.
Early / mixed evidenceExplore the studies →Cellular stress & ageing
Antioxidant and cell-maintenance mechanisms underpin broader healthy-ageing interest.
In-vitro and animal studies report multiple signalling effects, but no validated healthspan endpoint in people.
Preclinical evidenceExplore the studies →Retinal research
A small clinical literature has explored retinal degeneration.
A 2002 report described clinical effects in retinitis pigmentosa, but modern controlled replication is lacking.
Limited human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availablePineal-regulating tetrapeptide Epitalon in retinitis pigmentosa ↗
People with degenerative retinal lesions / retinitis pigmentosa
The publication reported positive clinical observations in retinal degeneration.
The PubMed record does not provide the modern protocol detail needed to establish a reproducible dose, and independent replication is lacking.
Epitalon increases telomere length in human cell lines ↗
Normal fibroblast and epithelial cells plus breast-cancer cell lines
Cell culture exposure4 days or 3 weeks, depending on cell line
Normal cells showed telomere-length changes alongside hTERT expression and telomerase activity.
Breast-cancer cell lines also showed ALT-related lengthening; this is a laboratory finding, not proof of benefit or harm in people.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
Small, older or region-specific human reports exist, without a robust modern trial programme.
✓
Clinical efficacyEarly
1/5 evidence depth
No trial establishes general anti-ageing, sleep or longevity efficacy.
◇
Safety evidenceEarly
1/5 evidence depth
Long-term systemic safety and cancer-relevant telomere effects remain uncertain.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Cell and animal studies support telomerase, circadian and stress-response hypotheses.
HOW TO READ THESE SCORESDeveloping preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEEpitalonMechanism → translation → human outcome
Small, older regional reports; no modern longevity programme
Cell and animal work across telomeres and pineal signalling
Human pharmacology, replication and long-term safety
What this snapshot does—and does not—show
It separates biological plausibility from demonstrated benefit. A compelling mechanism can justify better trials; it cannot substitute for them.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Epitalon
People explore Epitalon for sleep, recovery and longevity because its research story connects the pineal gland with telomeres. The leap from cell findings to longer or healthier human life remains very large.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Sleep rhythm and waking refreshed
Circadian and pineal-related research attracts interest in more regular sleep and better morning readiness. These immediate goals are different from the much larger longevity claims surrounding the compound.
- What makes a report informative
- Sleep timing, continuity and next-day function.
- What can muddy the picture
- Season, routines, stress and other sleep products can explain changes.
Healthy ageing and telomere interest
People are interested in maintaining vitality and delaying age-related decline. Telomere findings make the story compelling, but a laboratory cellular result cannot tell someone that taking Epitalon will extend their life.
- What makes a report informative
- Specific functional outcomes and the type of evidence cited.
- What can muddy the picture
- Cell-culture telomere changes are not human healthspan or lifespan outcomes.
Feeling restored after demanding periods
Some interest centres on a subjective reset or rejuvenation after stress and poor sleep. A useful account makes that description concrete: what became easier and how long did it last?
- What makes a report informative
- Everyday capability, sleep and persistence of any perceived change.
- What can muddy the picture
- Rest taken alongside a short course can be an important competing explanation.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Longer telomeres and longevity
Telomere claims dominate online descriptions of Epitalon.
Human findings & limits
There is no robust clinical trial showing longer life or improved healthspan.
Laboratory & animal context
Cell studies report telomerase and telomere effects; animal ageing studies provide additional hypotheses.
What this means: A real laboratory signal that does not yet establish a longevity benefit.
Sleep and circadian rhythm
Pineal and melatonin language drives sleep-related use.
Human findings & limits
Modern controlled insomnia trials are lacking.
Laboratory & animal context
Pineal and melatonin-related effects have been reported in animal and laboratory studies.
What this means: Biologically interesting, clinically unproven for sleep.
Recovery and 'rejuvenation'
Users sometimes report broader wellbeing or recovery effects.
Human findings & limits
These non-specific outcomes are highly vulnerable to expectation and concurrent lifestyle changes.
Laboratory & animal context
Cell-stress and antioxidant findings offer possible mechanisms.
What this means: Community experience may generate questions, but does not establish rejuvenation.
Short-course longevity routines
Ten-to-twenty-day injection courses are repeated across community protocol descriptions.
Human findings & limits
No controlled human study has validated the commonly shared amount, course length or repeat interval for healthy ageing.
Laboratory & animal context
Laboratory concentration and animal exposure cannot be converted directly into a personal injection protocol.
What this means: A recognisable community pattern—not a clinically established anti-ageing schedule.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA short-course pattern with no validated titration
This is a recurring community description for subcutaneous Epitalon—not a dose established by a human longevity trial.
1Days 1–3
5 mg · once dailyConservative community-described start
2Days 4–10
5–10 mg / daySome descriptions increase; evidence does not require it
3Days 11–20
Continue or stopCourse length varies across anecdotal protocols
4After course
Long pause & reviewNo evidence-based repeat interval
What people commonly discuss5–10 mg once daily for 10–20 days, followed by a pause that may last several months.
What remains unvalidatedNo controlled human study validates this amount, step-up, course length, anti-ageing outcome or repeat schedule.
ROUTE & DELIVERYSubcutaneous is the common community route
Oral and nasal descriptions also appear, but bioavailability and route equivalence have not been characterised in people.
PROFESSIONAL SOURCE CONTEXT
Epitalon telomere study · human cells, not dosing ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Epitalon has no validated general anti-ageing or sleep dose, titration method or maintenance schedule.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · no established human longevity doseWhat people commonly discuss
STARTING APPROACHES
Community descriptions often begin around 5 mg per day; 10 mg per day also appears, usually by subcutaneous injection.
DURATION / CYCLES
Short 10–20-day courses are more commonly discussed than continuous use.
MAINTENANCE DISCUSSION
A long pause—often several months—may be described before another course, but no evidence-based repeat interval exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Twenty-day editorial example
Community example · not clinically validatedThis is a short course described in community material. Pineal-extract studies and laboratory telomere findings do not establish this synthetic peptide regimen.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Days 1–20 | 5 mg |
Frequency: Every day · 1 entry per scheduled day.
The copy stops after exactly twenty days. The editorial break and any repeat course are not added.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Epitalon
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDEpitalon
→
OFTEN EXPLORED WITHEpitalon + DSIP
Epitalon + DSIP
→
OFTEN EXPLORED WITHEpitalon + NAD+ precursors
Epitalon + NAD+ / NR / NMN
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
EEPITALON IS USUALLY DISCUSSED AROUNDCircadian, pineal and cellular-ageing hypotheses
＋Its appeal spans sleep timing and telomere biology, but neither is an established general anti-ageing treatment.
PTHE PAIRED APPROACH MAY ADDSleep support or a separate cellular-energy story
DSIP and NAD-related approaches are discussed for different reasons; no study establishes synergy with Epitalon.
＋
OFTEN EXPLORED WITH
Explore →＋Epitalon + DSIP
Epitalon + DSIPWHY IT IS EXPLOREDExplored around circadian, sleep and recovery themes.
No combination-specific human evidence.OFTEN EXPLORED WITH
Explore →Epitalon + NAD+ precursors
Epitalon + NAD+ / NR / NMNWHY IT IS EXPLOREDPopular in longevity discussions combining telomere and cellular-energy stories.
The components have separate evidence profiles; synergy is unproven.01Define the outcome
Sleep quality, circadian timing, biomarkers and longevity are different questions.
02Do not merge mechanisms
Two interesting ageing pathways do not become evidence for a combined healthspan effect.
03Keep monitoring independent
Each component retains its own interactions, product-quality risks and evidence gaps.
Safety context
SAFETY & UNCERTAINTY
Telomere activity needs careful interpretation
01ENCOURAGING CONTEXTA defined peptide with testable biology
Recent laboratory work gives the telomere hypothesis a measurable mechanism rather than relying only on broad longevity language.
02THE IMPORTANT BOUNDARYTelomere change is not automatically beneficial
Effects were observed in normal and cancer cell lines. That does not prove harm, but it makes casual anti-ageing claims scientifically inappropriate.
03WHAT REMAINS UNKNOWNHuman exposure and long-term outcomes
Pharmacokinetics, dose-response, cancer-relevant effects and multi-year safety have not been established in a modern programme.
What the current evidence saysLonger telomeres are not automatically beneficial, and the 2025 study observed effects in cancer cell lines as well as normal cells. That does not prove harm, but it reinforces the need for human pharmacology and long-term safety research.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
A past or active malignancy changes how uncertain telomere-active biology should be considered.
Identity, purity, degradation, concentration and sterility are separate product-level risks.
Short-term subjective change cannot demonstrate slower ageing, longer telomeres or longer life.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
6 sourcesSources used on this profile
Bibliographic recordPineal-regulating tetrapeptide Epitalon in retinitis pigmentosaPubMed ↗Original laboratory publicationEpitalon increases telomere length in human cell linesFree full paper ↗Original publicationEpitalon increases telomere length in human cell linesJournal / DOI ↗Bibliographic recordEpitalon increases telomere length in human cell linesPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Epitalon is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.